Bristol Valuation

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Do you wonder what the value of Bristol Myers Squibb is? Bristol Myers Cash and Equivalents Turnover is fairly stable at the moment as compared to the past year. Bristol Myers reported Cash and Equivalents Turnover of 2.72 in 2019. Net Cash Flow or Change in Cash and Cash Equivalents is likely to grow to about 6.4 B in 2020, whereas Free Cash Flow is likely to drop slightly above 6.1 B in 2020. Bristol Myers Squibb shows a prevailing Real Value of $62.25 per share. The current price of the firm is $57.89. At this time, the firm appears to be undervalued. Our model approximates the value of Bristol Myers Squibb from analyzing the firm fundamentals such as return on equity of 3.00 %, profit margin of 3.08 %, and current valuation of 164.04 B as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.

Search Valuation

 
Refresh
Bristol Myers Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Bristol Myers's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today
57.89
15th of July 2020
62.25
Real Value
63.69
Upside
Bristol Myers is very steady asset. Calculation of real value of Bristol Myers Squibb is based on 3 months time horizon. Increasing Bristol Myers Squibb time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.
Earnings
Estimates (6)
LowProjected EPSHigh
6.086.176.20
Details
Hype
Prediction
LowEstimated ValueHigh
56.3557.7959.23
Details
12 Analysts
Consensus
LowTarget PriceHigh
50.0065.7880.00
Details

  Bristol Myers Investments

Bristol Valuation Drivers Correlation

Many accounts on the financial statements of Bristol Myers Squibb are highly interrelated and sometimes correlated. Consequently, when conducting Bristol's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Bristol
Click cells to compare fundamentals   

Bristol Market Cap

Bristol Myers Squibb is rated below average in market capitalization category among related companies. Market capitalization of Drug Manufacturers?General industry is currently estimated at about 1.55 Trillion. Bristol Myers holds roughly 131.48 Billion in market capitalization claiming about 9% of equities under Drug Manufacturers?General industry.
Capitalization  Total debt  Workforce  Valuation  Revenue

Bristol Myers Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info.
Bristol Myers Squibb is rated below average in last dividend paid category among related companies. It is rated below average in five year return category among related companies reporting about  6.09  of Five Year Return per Last Dividend Paid. . Return on Investment is likely to grow to 15.40 in 2020. Return on Average Assets is likely to grow to 0.07 in 2020

About Bristol Myers Valuation

The Macroaxis Equity Valuation Mechanism determines the current worth of Bristol Myers Squibb on a weekly bases. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Bristol Myers Squibb. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Bristol Myers Squibb based exclusively on its fundamental and basic technical indicators. By analyzing Bristol Myers's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Bristol Myers's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bristol Myers. We calculate exposure to Bristol Myers's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Bristol Myers's related companies.
Last ReportedProjected for 2020
Gross Profit18.1 B17.7 B
Profit Margin 0.13  0.14 
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 30000 people.

Bristol Myers Dividends Analysis For Valuation

Bristol Myers Dividend Yield is fairly stable at the moment as compared to the past year. Bristol Myers reported Dividend Yield of 0.026 in 2019. Dividends per Basic Common Share is likely to grow to 1.68 in 2020, whereas Payment of Dividends and Other Cash Distributions is likely to drop (2.9 B) in 2020. . Bristol Myers Accumulated Retained Earnings Deficit are fairly stable at the moment as compared to the past year. Bristol Myers reported Accumulated Retained Earnings Deficit of 34.47 Billion in 2019. Price to Earnings Ratio is likely to grow to 37.29 in 2020, whereas Earning Before Interest and Taxes EBIT is likely to drop slightly above 4.6 B in 2020.
Last ReportedProjected for 2020
Payment of Dividends and Other Cash Distributions-2.7 B-2.9 B
Dividend Yield 0.026  0.0269 
Dividends per Basic Common Share 1.64  1.68 
There are various types of dividends Bristol Myers can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Bristol shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Bristol Myers Squibb directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Bristol pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Bristol Myers by the value of the dividends paid out.

Bristol Myers Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Bristol Myers does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio1.38
Revenue Growth82.10%
Payout Ratio273.02%
Enterprise Value To Ebitda14.17
Enterprise Value To Revenue5.29

Bristol Myers Current Valuation Indicators

Valuation refers to the process of determining the present value of Bristol Myers Squibb and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Bristol we look at many different elements of the entity such as Bristol's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Book Value per Share
Enterprise Value over EBIT
Enterprise Value over EBITDA
Price to Book Value
Continue to Trending Equities. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page